Un equipo de investigadores de la Universidad de Monash ha identificado nuevos marcadores epigenéticos que predicen el desarrollo de enfermedad renal en personas con diabetes. Los resultados de su tr...
Read moreResearchers from the public and private sectors of nine European countries are partnering up for the LUCIA project (Understanding Lung Cancer-Related Risk Factors and their Impact), which seeks to imp...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read moreThe epigenetics in stem cells and cancer research group of the ibs.GRANADA and the University of Granada, has provided new data to understand how the human body is formed from a single initial cell or...
Read moreOryzon Genomics S.A. announced that it will host a virtual panel discussion discussing the unmet medical needs in specific central nervous system (CNS) and oncology diseases, such as Borderline Person...
Read moreUn análisis de sangre que combina la determinación de PSA y biomarcadores de expresión detecta el cáncer de próstata con un 94% de precisión.
Read moreEl Instituto de Investigación Sanitaria INCLIVA y la Fundación Valenciana de Agricultura y Medio Ambiente (FUVAMA) han impulsado una investigación para analizar las propiedades nutricionales de las...
Read moreThe Hematopoietic Stem Cell Biology and Leukemogenesis group at IDIBELL, headed by Dr Alessandra Giorgetti, associate professor at University of Barcelona has discovered an additional level of gene re...
Read moreOryzon Genomics, S.A, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological dise...
Read moreOryzon Genomics announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (A...
Read more18 pacientes con leucemia aguda han experimentado remisión completa de la enfermedad tras ser tratados con el fármaco experimental revumenib. El fármaco, que se administra en forma de pastilla oral...
Read moreInvestigadores del grupo Hormonas y Cáncer del IMIBIC, la Universidad de Córdoba y el Hospital Universitario Reina Sofía han participado en la caracterización molecular más avanzada hasta la fech...
Read more